We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
Read MoreHide Full Article
Key Takeaways
Liquidia's preliminary Q3 Yutrepia sales rose to $222.7 million from $170.4 million in Q2.
A $380.7 million settlement with United Therapeutics could pressure cash flow and commercial investment.
Higher R&D and SG&A costs may weigh on profitability as Liquidia advances 10 clinical studies.
Liquidia Corporation (LQDA - Free Report) is expected to report its third-quarter 2026 results next month. Investors will likely focus on the continued sales growth of its marketed drug, Yutrepia, pipeline progress and the company’s path to profitability. The financial impact of its recent legal settlement with United Therapeutics (UTHR - Free Report) will also be a key factor to watch.
In the last reported quarter, the company delivered an earnings surprise of 5.71%.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $187 million, while the same for earnings is pinned at 77 cents per share.
Let us see how things might have shaped up for LQDA in the to-be-reported quarter.
Factors Likely to Influence LQDA’s Q3 Results
Yutrepia was approved in 2025 for the treatment of pulmonary arterial hypertension (PAH). It is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device.
The company has already reported preliminary third-quarter Yutrepia sales of $222.7 million, up from $170.4 million in the second quarter. Strong prescription growth and patient demand have supported Yutrepia’s sales in recent quarters. The preliminary third-quarter sales figure points to continued commercial momentum. The drug was also approved for PH-ILD, but Liquidia has agreed to remove this indication following its legal settlement with United Therapeutics. The loss of this indication could narrow Yutrepia’s addressable market and limit its future sales potential.
Hence, investors will focus on details on new prescriptions, patient starts and demand trends.
In October 2026, Liquidia settled with United Therapeutics, resolving all six ongoing legal disputes between the companies. Under the agreement, Liquidia will make net payments totaling $380.7 million in installments during 2026 and 2027.
While the settlement removes significant legal uncertainty, the payments could put pressure on cash flow and reduce the funds available for commercial operations and pipeline development.
Higher research and development (R&D) expenses, as well as increased selling, general and administrative (SG&A) costs, are likely to have escalated operating expenses in the third quarter of 2026.
Liquidia reported preliminary cash and cash equivalents of $396.1 million at September-end. Investors will focus on additional updates on the company’s plan to manage liquidity post-UTHR payments and whether existing cash resources can maintain profitability and manage its cash position while meeting its settlement obligations and funding its pipeline.
Beyond Yutrepia, Liquidia is developing L606, an investigational extended-release formulation of treprostinil delivered through a portable nebulizer. The twice-daily treatment is being evaluated for PAH and PH-ILD.In its second-quarter update, Liquidia reported that enrollment had begun in the pivotal Re-Spire study for the treatment of PH-ILD. The company has 10 clinical studies involving Yutrepia and L606 either underway or planned to begin over the following 12 months. Investors will look for updates on clinical progress in the soon-to-be-reported quarter.
Earnings Surprise History
Liquidia has an impeccable earnings track record. It beat earnings estimates in each of the trailing four quarters, delivering an average earnings surprise of 59.32%.
LQDA’s Stock Performance
Year to date, shares of Liquidia have gained 31.7% compared with the industry’s 6% growth.
Image Source: Zacks Investment Research
Earnings Whispers for LQDA
Our proven model does not conclusively predict an earnings beat for LQDA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
LQDA's Earnings ESP: Liquidia has an Earnings ESP of -1.30% as the Most Accurate Estimate currently stands at earnings of 76 cents per share and the Zacks Consensus Estimate for the same is pegged at 77 cents.
Zacks Rank of Liquidia: Liquidia currently carries a Zacks Rank #5 (Strong Sell).
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present.
Shares of TGTX have gained 89.4% year to date. The company’s earnings missed estimates in three of the trailing four quarters and topped in the remaining one, delivering the average surprise of 184.65%.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +22.22% and a Zacks Rank #2 at present.
Shares of IOVA have skyrocketed 434% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering the average surprise of 16.82%. Iovance Biotherapeutics is scheduled to report its third-quarter results on Nov. 5.
View the Zacks #1 Rank List
Image: Bigstock
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
Key Takeaways
Liquidia Corporation (LQDA - Free Report) is expected to report its third-quarter 2026 results next month. Investors will likely focus on the continued sales growth of its marketed drug, Yutrepia, pipeline progress and the company’s path to profitability. The financial impact of its recent legal settlement with United Therapeutics (UTHR - Free Report) will also be a key factor to watch.
In the last reported quarter, the company delivered an earnings surprise of 5.71%.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $187 million, while the same for earnings is pinned at 77 cents per share.
Let us see how things might have shaped up for LQDA in the to-be-reported quarter.
Factors Likely to Influence LQDA’s Q3 Results
Yutrepia was approved in 2025 for the treatment of pulmonary arterial hypertension (PAH). It is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device.
The company has already reported preliminary third-quarter Yutrepia sales of $222.7 million, up from $170.4 million in the second quarter. Strong prescription growth and patient demand have supported Yutrepia’s sales in recent quarters. The preliminary third-quarter sales figure points to continued commercial momentum. The drug was also approved for PH-ILD, but Liquidia has agreed to remove this indication following its legal settlement with United Therapeutics. The loss of this indication could narrow Yutrepia’s addressable market and limit its future sales potential.
Hence, investors will focus on details on new prescriptions, patient starts and demand trends.
In October 2026, Liquidia settled with United Therapeutics, resolving all six ongoing legal disputes between the companies. Under the agreement, Liquidia will make net payments totaling $380.7 million in installments during 2026 and 2027.
While the settlement removes significant legal uncertainty, the payments could put pressure on cash flow and reduce the funds available for commercial operations and pipeline development.
Higher research and development (R&D) expenses, as well as increased selling, general and administrative (SG&A) costs, are likely to have escalated operating expenses in the third quarter of 2026.
Liquidia reported preliminary cash and cash equivalents of $396.1 million at September-end. Investors will focus on additional updates on the company’s plan to manage liquidity post-UTHR payments and whether existing cash resources can maintain profitability and manage its cash position while meeting its settlement obligations and funding its pipeline.
Beyond Yutrepia, Liquidia is developing L606, an investigational extended-release formulation of treprostinil delivered through a portable nebulizer. The twice-daily treatment is being evaluated for PAH and PH-ILD.In its second-quarter update, Liquidia reported that enrollment had begun in the pivotal Re-Spire study for the treatment of PH-ILD. The company has 10 clinical studies involving Yutrepia and L606 either underway or planned to begin over the following 12 months. Investors will look for updates on clinical progress in the soon-to-be-reported quarter.
Earnings Surprise History
Liquidia has an impeccable earnings track record. It beat earnings estimates in each of the trailing four quarters, delivering an average earnings surprise of 59.32%.
LQDA’s Stock Performance
Year to date, shares of Liquidia have gained 31.7% compared with the industry’s 6% growth.
Image Source: Zacks Investment Research
Earnings Whispers for LQDA
Our proven model does not conclusively predict an earnings beat for LQDA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
LQDA's Earnings ESP: Liquidia has an Earnings ESP of -1.30% as the Most Accurate Estimate currently stands at earnings of 76 cents per share and the Zacks Consensus Estimate for the same is pegged at 77 cents.
Zacks Rank of Liquidia: Liquidia currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Liquidia Corporation Price and Consensus
Liquidia Corporation price-consensus-chart | Liquidia Corporation Quote
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present.
Shares of TGTX have gained 89.4% year to date. The company’s earnings missed estimates in three of the trailing four quarters and topped in the remaining one, delivering the average surprise of 184.65%.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +22.22% and a Zacks Rank #2 at present.
Shares of IOVA have skyrocketed 434% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering the average surprise of 16.82%. Iovance Biotherapeutics is scheduled to report its third-quarter results on Nov. 5.